TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5723-5731

  Dierynck, Inge ^a   Van Marck, Herwig ^a   Van Ginderen, Marcia ^a   Jonckers, Tim H M ^a   Nalam, Madhavi N L ^b   Schiffer, Celia A ^b   Raoof, Araz ^a   Kraus, Guenter ^a   Picchio, Gaston ^c  

^a TIBOTEC BVBA   (Belgium)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; ARGININE; ATAZANAVIR; DARUNAVIR; GLUTAMIC ACID; GLYCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; ISOLEUCINE; LOPINAVIR; LYSINE; PHENYLALANINE; SAQUINAVIR; SERINE; TIPRANAVIR; TMC 310911; UNCLASSIFIED DRUG; VALINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MUTANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN; WILD TYPE;

CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; SULFONAMIDES;

EID: 81555201923     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00748-11     Document Type: Article

References (36)

1. Arastéh, K., et al. 2009. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 14:859-864.
2. Arribas, J. R. 2009. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Curr. Opin. HIV AIDS 4:507-512.
3. Braun, P., et al. 2007. Clinically relevant resensitization of protease inhibitors (PIs) saquinavir and atazanavir (ATV) by L76V mutations in multidrug-resistant HIV-1-infected patients, abstr. 129. Antivir. Ther. 12:S142.
4. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
5. De Meyer, S., et al. 2006. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors, abstr. 19. Antivir. Ther. 11:S24.
6. De Meyer, S., et al. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321. (Pubitemid 40734460)
7. De Meyer, S., et al. 2008. Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2, abstr. 31. Antivir. Ther. 13(Suppl. 3):A33.
8. De Meyer, S., et al. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retroviruses 24:379-388. (Pubitemid 351457745)
9. Division of AIDS, National Institute of Allergy and Infectious Diseases. 1997. DAIDS virology manual for HIV laboratories. Publication NIH-97-3828. U.S. Department of Health and Human Services, Washington, DC.
10. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. (Pubitemid 41742764)
11. Hertogs, K., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276. (Pubitemid 28114430)
12. Johnson, V. A., et al. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17:138-145.
13. Jones, T. A., M. Bergdoll, and M. Kjeldgaard. 1990. O: a macromolecular modeling environment, p. 189-195. In C. Bugg and S. Ealick (ed.), Crystallographic and modeling methods in molecular design. Springer-Verlag Press, Berlin, Germany.
14. King, N. M., et al. 2002. Lack of synergy for inhibitors targeting a multidrug-resistant HIV-1 protease. Protein Sci. 11:418-429. (Pubitemid 34075805)
15. King, N. M., et al. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021. (Pubitemid 39390785)
16. Koh, Y., et al. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J. Virol. 84:11961-11969.
17. Koh, Y., et al. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282:28709-28720. (Pubitemid 47606016)
18. Kuriyan, J., and W. I. Weis. 1991. Rigid protein motion as a model for crystallographic temperature factors. Proc. Natl. Acad. Sci. U. S. A. 88:2773-2777. (Pubitemid 21916501)
19. Larder, B. A., et al. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
20. Luna, B., and M. U. Townsend. 2007. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin. Ther. 29:2309-2318. (Pubitemid 350298126)
21. Madruga, J. V., et al. 2007. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 370:49-58. (Pubitemid 47023100)
22. Mills, A. M., et al. 2009. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23:1679-1688.
23. Minor, W. 1993. XDISPLAYF (program). Purdue University, West Lafayette, IN.
24. Mo, H., et al. 2003. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Res. 59:173-180. (Pubitemid 36966749)
25. Morris, R. J., A. Perrakis, and V. S. Lamzin. 2002. ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr. D Biol. Crystallogr. 58:968-975. (Pubitemid 34653026)
26. Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255. (Pubitemid 27235885)
27. Navaza, J. 1994. AMoRe: an automated package for molecular replacement. Acta Cryst. A 50:157-163.
28. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. (Pubitemid 27085611)
29. Perno, C. F., and R. Yarchoan. 1993. Culture of HIV in monocytes and macrophages, p. 12.4.1-12.4.11. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, vol 3. John Wiley & Sons, New York, NY.
30. Pomerantz, R. J., and D. L. Horn. 2003. Twenty years of therapy for HIV-1 infection. Nat. Med. 9:867-873. (Pubitemid 36889928)
31. Stawiski, E., et al. 2010. Identification of novel mutations strongly associated with darunavir (DRV) and tipranavir (TPV) resistance and their trends in a commercial database, abstr. H-912. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
32. Surleraux, D. L. N. G., et al. 2005. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J. Med. Chem. 48:1965-1973. (Pubitemid 40403065)
33. Surleraux, D. L. N. G., et al. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48:1813-1822. (Pubitemid 40396314)
34. Van Der Borght, K., et al. 2006. The effects of the 76V mutation on protease inhibitor (PI) susceptibility are PI- and context-specific, abstr. THPE0038. Abstr. 16th Int. AIDS Conf., Toronto, Canada.
35. Vermeiren, H., et al. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 145:47-55. (Pubitemid 47247892)
36. Wilson, L. E., and J. E. Gallant. 2009. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin. Infect. Dis. 48:214-221.